Evidence map›Paper›PMID 37671067›Full record

ArticleNeuroprotection (Chichester, England)2023

Exploiting moderate hypoxia to benefit patients with brain disease: Molecular mechanisms and translational research in progress.

Hannelore Ehrenreich, Max Gassmann, Luise Poustka, Martin Burtscher, Peter Hammermann, Anna-Leena Sirén, Klaus-Armin Nave, Kamilla Miskowiak

Open access · diamondAbstract read
In one paragraph

Article in Neuroprotection (Chichester, England), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
4.1field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 17 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 6 institutions in 4 countries.

Hannelore EhrenreichClinical Neuroscience, Max Planck Institute for Multidisciplinary Sciences, Göttingen, Germany.ORCID https://orcid.org/0000-0001-8371-5711
Max GassmannInstitute of Veterinary Physiology and Zürich Center for Integrative Human Physiology, University of Zürich, Zürich, Switzerland.
Luise PoustkaDepartment of Child and Adolescent Psychiatry and Psychotherapy, University Medical Center Göttingen, Göttingen, Germany.
Martin BurtscherFaculty of Sports Science, University of Innsbruck, Innsbruck, Austria.
Peter HammermannHBL Investmentpartners GmbH, München-Frankfurt, Germany.
Anna-Leena SirénDepartments of Neurophysiology and Neurosurgery, University of Würzburg, Würzburg, Germany.
Klaus-Armin NaveDepartment of Neurogenetics, Max Planck Institute for Multidisciplinary Sciences, Göttingen, Germany.
Kamilla MiskowiakPsychiatric Centre, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.
Max Planck Institute for Multidisciplinary SciencesUniversität Innsbruck · ATUniversitätsmedizin Göttingen · DEUniversity of Copenhagen · DKUniversity of Würzburg · DEUniversity of Zurich · CH

Funding

European Research Council 101054369
6 · The paper itself

Abstract

Hypoxia is increasingly recognized as an important physiological driving force. A specific transcriptional program, induced by a decrease in oxygen (O

Indexed as

brain EPO circleerythropoietinfunctional hypoxiaHIFhuman pilot studyhyperoxiainspiratory oxygen manipulationsmotor-cognitive performancePBMCtranslation

Identifiers

PMID37671067
PMCPMC7615021
OpenAlexW4321498086

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.